The 2020 Innovation Contest held by Boehringer Ingelheim is the first biomedical innovation competition sponsored by multinational pharmaceutical company in China, aiming to develop collaborations and partnerships with Chinese innovative enterprises or individuals and stimulate local innovation. CommBio was successfully shortlisted for the final and won the most industry attention award. Dr. Xiang said after the competition: "It is an honor to participate in the BI Innovation Contest and receive the attention, which is an encouragement for CommBio to adhering to our mission of innovation. This also shows a new understanding of " innovation" in the Chinese drug development industry. We believe that "original and innovative drugs" will gradually become the mainstream of biomedical development in China."